Singular Genomics Financials
| OMIC Stock | USD 21.90 0.09 0.41% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.99 | 10.5117 |
|
|
The essential information of the day-to-day investment outlook for Singular Genomics includes many different criteria found on its balance sheet. An individual investor should monitor Singular Genomics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Singular Genomics.
Net Income |
|
Singular | Select Account or Indicator |
Understanding current and past Singular Genomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Singular Genomics' financial statements are interrelated, with each one affecting the others. For example, an increase in Singular Genomics' assets may result in an increase in income on the income statement.
Please note, the presentation of Singular Genomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Singular Genomics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Singular Genomics' management manipulating its earnings.
Singular Genomics Stock Summary
Singular Genomics competes with InfuSystems Holdings, Pro Dex, LeMaitre Vascular, Utah Medical, and Milestone Scientific. Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California. Singular Genomics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 248 people.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US82933R1005 |
| CUSIP | 82933R100 82933R308 |
| Location | California; U.S.A |
| Business Address | 3010 Science Park |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.singulargenomics.com |
| Phone | 858 333 7830 |
| Currency | USD - US Dollar |
Singular Genomics Key Financial Ratios
| Return On Equity | -0.52 | ||||
| Operating Margin | (30.94) % | ||||
| Price To Sales | 20.11 X | ||||
| Revenue | 2.91 M | ||||
| Gross Profit | (24 K) |
Singular Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Singular Genomics's current stock value. Our valuation model uses many indicators to compare Singular Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Singular Genomics competition to find correlations between indicators driving Singular Genomics's intrinsic value. More Info.Singular Genomics Systems is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Singular Genomics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Singular Genomics' earnings, one of the primary drivers of an investment's value.Singular Genomics Systems Systematic Risk
Singular Genomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Singular Genomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Singular Genomics Systems correlated with the market. If Beta is less than 0 Singular Genomics generally moves in the opposite direction as compared to the market. If Singular Genomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Singular Genomics Systems is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Singular Genomics is generally in the same direction as the market. If Beta > 1 Singular Genomics moves generally in the same direction as, but more than the movement of the benchmark.
Singular Genomics Thematic Clasifications
Singular Genomics Systems is part of several thematic ideas from Office Supplies to Measuring and Control Equipment. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Singular Genomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Singular Genomics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Singular Genomics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Singular Genomics November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Singular Genomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Singular Genomics Systems. We use our internally-developed statistical techniques to arrive at the intrinsic value of Singular Genomics Systems based on widely used predictive technical indicators. In general, we focus on analyzing Singular Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Singular Genomics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.07 | |||
| Information Ratio | 0.1514 | |||
| Maximum Drawdown | 129.25 | |||
| Value At Risk | (6.36) | |||
| Potential Upside | 12.24 |
Complementary Tools for Singular Stock analysis
When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |